Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Pharmacol Ther. 2020 Oct 9;219:107704. doi: 10.1016/j.pharmthera.2020.107704

Figure 3: MLK3 gene (i.e. MAP3K11) expression in solid malignancies.

Figure 3:

The MAP3K11 expressions were analyzed in bladder, brain, ovarian, breast, and colorectal cancers using the cancer genome atlas (TCGA) with the Oncomine™ Platform (Thermo Fisher, Ann Arbor, MI). (A) The MAP3K11 gene expressions in bladder cancer, where bladder (n=24), BUC (n=14), IBUC (n=99) and IBUC MV (n=38). (B) The MAP3K11 gene expressions in Brain cancer, where brain (n=10), BG (n=542), and G (n=5). (C) The MAP3K11 gene expressions in ovarian cancer, where ovary (n=8) and OSC (n=586). (D) The MAP3K11 gene expressions in breast cancer, where breast (n=61), IBC (n=76), IDBC (n=389), ILBC (n=36) and MLDBC (n=7). (E) The MAP3K11 gene expressions in colorectal cancer, where colon (n=19), cecum A (n=24), colon A (n=102), CMA (n=20), RA (n=60) and RMA (n=6). Where, BUC, urothelial bladder carcinoma; IBUC, infiltrating bladder urothelial carcinoma; MV, micropapillary variant; MLK3, mixed lineage kinase 3; BG, brain glioblastoma; G, glioblastoma; OSC, ovarian serous cystadenocarcinoma; IBC, invasive breast carcinoma; IDBC, invasive ductal breast carcinoma; ILBC, invasive lobular breast carcinoma; MLDBC, mixed lobular and ductal breast carcinoma; Cecum A, cecum adenocarcinoma; Colon A, colon adenocarcinoma; CMA, colon mucinous adenocarcinoma; RA, rectal adenocarcinoma; RMA, rectal mucinous adenocarcinoma.